Kymera surges 51% YTD as oral STAT6 degrader accelerates toward pivotal data

Kymera Therapeutics has pulled its Phase 2b atopic dermatitis data forward by six months, setting up a year-end 2026 catalyst that could reshape the $25 billion type 2 inflammation market.

Kymera Therapeutics Inc. completed enrollment in its Phase 2b BROADEN2 trial of oral STAT6 degrader KT-621 for moderate-to-severe atopic dermatitis about six months ahead of schedule, pulling topline data to year-end 2026 from mid-2027 and positioning the drug as a potential oral challenger to Sanofi and Regeneron Pharmaceuticals Inc.'s blockbuster injectable Dupixent.

"The accelerated enrollment signals strong clinician enthusiasm for an oral drug that could deliver biologic-like efficacy without injections," Truist Securities analysts wrote in a June 29 note, raising their price target on Kymera to $136 from $116 while maintaining a Buy rating.

Shares of the Watertown, Massachusetts-based company have gained 50.9% year to date, outperforming the industry's 6.4% advance, and trade at a market capitalization of about $8.75 billion. The stock has returned 145% over the past 12 months. Phase 1b data presented at the American Academy of Dermatology Annual Meeting in March showed KT-621 achieved 98% STAT6 degradation in blood and 94% in lesional skin, with a 63% mean reduction in Eczema Area and Severity Index scores at day 29. Seventy-six percent of patients achieved EASI 50, and 19% reached a vIGA-AD score of 0 or 1 — clear or almost clear skin — with no serious adverse events, conjunctivitis, or herpes infections reported.

An effective oral therapy for atopic dermatitis and asthma — two indications with a combined addressable market exceeding $25 billion — could capture significant share from Dupixent, which generated more than $13 billion in 2025 sales and requires biweekly injections. Kymera plans to begin Phase 3 studies in atopic dermatitis by mid-2027, pending regulatory discussions, while a separate Phase 2b trial in eosinophilic asthma is expected to read out in late 2027.

Beyond KT-621, Kymera's pipeline extends across three additional programs that validate its targeted protein degradation platform. The company's collaboration with Sanofi on KT-485, an oral IRAK4 degrader for hidradenitis suppurativa, triggered a $20 million milestone payment last month when the first participant was dosed in a Phase 1 study. Sanofi is responsible for development and commercialization, with Kymera eligible for up to $975 million in additional milestone payments.

In April, Gilead Sciences Inc. exercised its option to exclusively license KT-200, a first-in-class oral CDK2 molecular glue degrader for breast cancer and other solid tumors, triggering a $45 million payment to Kymera. The deal provides non-dilutive capital and validates the company's molecular glue platform, with an IND filing targeted for 2027.

Kymera is also advancing KT-579, an oral IRF5 degrader that showed disease-modifying activity in lupus models. A Phase 1 study in healthy volunteers is ongoing, with data expected in the second half of 2026.

The company ended the first quarter with sufficient cash to fund ongoing Phase 2b studies for KT-621, advance KT-579 into early proof-of-concept planning, and support continued pipeline expansion, management said in its May earnings call. Canaccord Genuity raised its price target to $129, and B. Riley lifted its target to $155, both maintaining Buy ratings.

Kymera shares, trading at a valuation that reflects limited product revenue through 2028, could re-rate significantly if KT-621 delivers positive Phase 2b data by year-end. The accelerated timeline concentrates both opportunity and risk into a shorter window: success would position Kymera as a leader in oral type 2 inflammation therapy, while any efficacy or safety miss would erase a substantial portion of the company's current enterprise value. Truist's $136 target implies about 28% upside from current levels, while B. Riley's $155 target suggests roughly 46% upside.

This article is for informational purposes only and does not constitute investment advice.